Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659376 | 0.86 | ACHE (0.69) | ACHECHRM5MAPTTP53HSP90AA1 | |
| SCHEMBL9904848 | 0.86 | ALDH3A1 (0.72) | CHRM5ALDH1A1ALDH2ALDH3A1CA12 | |
| SCHEMBL28070700 | 0.84 | ACHE (0.66) | ACHECHRM5MAPTTP53HSP90AA1 | |
| SCHEMBL28075277 | 0.84 | CA12 (0.67) | ACHECHRM5MAPTTP53HSP90AA1 | |
| SCHEMBL5659567 | 0.84 | ALDH1A1 (0.71) | ACHECHRM5ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL14740713 | 0.83 | CHRM5 (0.73) | CHRM5MAPTTP53ALDH1A1ALDH2 | |
| SCHEMBL578250 | 0.83 | ACHE (0.74) | ACHEMAPTTP53HSP90AA1ALDH1A1 | |
| SCHEMBL4609842 | 0.83 | CES1 (0.66) | ACHECHRM5MAPTTP53ALDH1A1 | |
| SCHEMBL18954858 | 0.82 | ACHE (0.63) | ACHECHRM5MAPTTP53HSP90AA1 | |
| SCHEMBL18954802 | 0.81 | CHRM5 (0.60) | ACHECHRM5ALDH1A1ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| CN-105541808-A | Metronidazole-isatin type compound as well as preparation method and application thereof | UNIV JISHOU | 2016-05-04 | — | — | CN | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1487792-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078394-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | XPOT, FANCI, XPO5 | ACHE 3598/4885CHRM5 4705/4885MAPT 2808/4885 |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | ACHE 4757/4885CHRM5 1591/4885MAPT 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.